United States human insulin market is
expected to show an exponential growth with an impressive CAGR in the forecast
period, 2023-2027. The market growth can be attributed to growing geriatric
population, increasing diabetic patients, rising prevalence of obesity, and -increasing
demand of better and efficient treatment. Increasing number of young populations
being infected of diabetes and irregular sugar level is increasing. This
increase in the number of young diabetics is anticipated to drive the growth of
the market growth in the next five years.
Technological advancements in the
devices and appliances making life easier and comfortable, are driving the
young adults toward obesity, lazy lifestyle and many health issues that
irregulates blood sugar level in their bodies, which is indirectly affecting
the growth of the United States human insulin market in the next five years. Cost-effectiveness,
reimbursement prices and strict regulatory requirements for approval of insulin
is anticipated to support the growth of the United States human insulin market
in the next five years.
Human insulin refers to synthetic
insulin which is laboratory grown to mimic the insulin in humans. The
laboratory created human insulin created by insulin proteins within E-coli
bacteria (Escherichia Coli). They are present in two forms short acting regular
form and neutral protamine hagedron (NPH) insulin form is also known as
isophane insulin which is a suspension meaning that the insulin vial should be
rolled or repeatedly turned upside down to ensure the solution is uniformly
cloudy.
The United States human insulin market
is segmented by indication, products, type, onset time, brand, competitional
landscape, and regional distribution. Based on indication, the market is
further bifurcated into type 1 diabetes, and type 2 diabetes. Type-I diabetes
is likely to hold the largest market share as human insulin is the most
important treatment method for the people suffering from type-I diabetes. The
population suffering from type 1 diabetes requires insulin therapy, and the
treatment focuses on managing blood sugar levels with insulin, diet, and
lifestyle, to prevent complications.
The R&D in the insulin segments are
rising year-on-year, as researchers are trying to bring out the best molecule
for patients' use, curbing out maximum side effects, and increasing their
efficiency. Thus, the increasing prevalence of obesity and diabetes across the
world is likely to augment considerable demand for insulin, and thus
anticipated to drive the growth of the market in the upcoming five years.
Holding largest shares of the market, a
partial list of the market players includes Novo Nordisk Inc., Sanofi-Aventis
US LLC, Eli Lilly and Company, Nektar Therapeutics, Mannkind Corporation, A-S
Medication Solutions, RemedyRepack Inc., Becton, Dickinson and Company, B.
Braun USA, Baxter International Inc., among others. The market players are
highly involved in the research and development of the technologically advanced
form of synthetic and laboratory synthesized human insulin.
Moreover, surge in
the demand of efficient and effective treatment for the diabetes and effective
method of administration along with the medical devices employed for the
administration of the human insulin is instigating more and diverse research
and development. Market players may adopt partnerships and acquisition as other
strategic recommendations.
Objective
of the Study:
- To
analyze the historical growth of the
market size of United States human insulin market from 2017 to 2020.
- To
estimate and forecast the market size of United States human insulin
market from 2021 to 2027 and growth rate until 2027.
- To classify and
forecast United States human insulin market based on indication, products,
type, onset time, brand, competitional landscape, and regional
distribution.
- To identify dominant region or segment in the United States human
insulin market.
- To
identify drivers and challenges for United States human insulin market.
- To
examine competitive developments such as expansions, new product launches,
mergers & acquisitions, etc., in United States human insulin market.
- To identify and analyze the profile
of leading players operating in United States human insulin market.
- To identify key sustainable strategies adopted by market players in
United States human insulin market.
Click here to download the sample
TechSci Research performed both primary as well as exhaustive
secondary research for this study. Initially, TechSci Research sourced a list
of manufacturers, suppliers, and service providers across the country.
Subsequently, TechSci Research conducted primary research surveys with the
identified companies. While interviewing, the respondents were also enquired
about their competitors. Through this technique, TechSci Research could include
the manufactures which could not be identified due to the limitations of
secondary research. TechSci Research analyzed the manufactures, distribution
channels and presence of all major players across the country.
TechSci Research calculated the market size of United States human insulin market using a bottom-up approach,
wherein data for various end-user segments was recorded and forecast for the
future years. TechSci Research sourced these values from the industry experts
and company representatives and externally validated through analyzing
historical data of these product types and applications for getting an
appropriate, overall market size. Various secondary sources such as company
websites, news articles, press releases, company annual reports, investor
presentations and financial reports were also studied by TechSci Research.
Key
Target Audience:
- Human insulin manufacturers, end users, and other stakeholders
- Distributers and suppliers of the products and other stakeholders
- Organizations, forums, and alliances related to human insulin products
- Market research and consulting firms
The study is useful in providing answers to several critical
questions that are important for the industry stakeholders such as manufacturers,
suppliers, end users, etc., besides allowing them in strategizing investments
and capitalizing on market opportunities.
|
Attribute
|
Details
|
|
Base
Year
|
2021
|
|
Historical
Years
|
2017 –
2020
|
|
Estimated
Year
|
2022E
|
|
Forecast
Period
|
2023F –
2027F
|
|
Quantitative
Units
|
Revenue in
USD Million and CAGR for 2017-2021 and 2022E-2027F
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered | - Indication
- Product
- Type
- Onset Time
- Brand
|
Region
Scope
|
South-Region,
West-Region, Mid-West Region & Northeast-Region
|
|
Key
Companies Profiled
|
Novo Nordisk
Inc., Sanofi-Aventis US LLC, Eli Lilly and Company, Nektar Therapeutics,
Mannkind Corporation, A-S Medication Solutions, RemedyRepack Inc., Becton,
Dickinson and Company, B. Braun USA, Baxter International Inc
|
|
Customization
Scope
|
10% free
report customization with purchase. Addition or alteration to regional &
segment scope.
|
|
Pricing
and Purchase Options
|
Avail
customized purchase options to meet your exact research needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also
provide the editable version of the report in PPT/Word format on special
request)
|
Report Scope:
In this report, United States human insulin market has been segmented into following
categories, in addition to the industry trends which have also been detailed
below:
- United States Human
Insulin Market, By Indication:
- Type 1 Diabetes
- Type 2 Diabetes
- United States Human Insulin Market,
By Products:
o Insulin Pens
o Insulin Pumps
o Infusion System
o Injection
- United States Human Insulin Market,
By Type:
o Basal
o Bolus
o Pre-Mixed
o Biosimilar
o Traditional
- United States Human Insulin Market,
By Onset Time:
- Rapid Acting
- Short Acting
- Intermediate Acting
- Long Lasting
- Others
- United States Human Insulin Market,
By Brand:
- Lantus
- Humulin R
- Novolin R
- Humulin N
- Exubera
- Others
- United States Human Insulin Market,
By Region:
- South West
- Mid-West
- North East
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in United States human insulin market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following customization
options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
United States Human Insulin
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]